Skip to main content
OpenTrials
Completed

NCT Number: NCT06547125

A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants For the Improvement of Skin Quality

Facial fine lines and wrinkles are caused by skin thinning, loss of moisture, and loss of elasticity due to factors such as age, ultraviolet (UV) radiation, and environmental exposures. Today, many injectable fillers are used to treat facial aging and correct skin defects. In this study, adverse effects and effectiveness of JUVÉDERM® VOLITE™ will be assessed in the treatment of fine lines and improving skin quality.

VOLITE is an investigational device being developed for improving skin quality. In this study, participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 3 chance that participants will be assigned to the no-treatment control group. Adult participants seeking improvement of skin quality, especially hydration and radiance, in the treatment area will be enrolled. Around 135 participants will be enrolled in the study at approximately 6 sites in China.

Participants in the treatment group will receive the initial injection of VOLITE; the control group will receive no treatment, but will have the opportunity to receive VOLITE after 2 months. Participants will be followed up for 12 months.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects, and completing questionnaires.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Skin Quality Deficit

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

China-Japan Friendship Hospital /ID# 260959, Beijing, Beijing Municipality, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Fitzpatrick skin types II-IV
  • Participants' FACE-Q Satisfaction with Skin Scale scores must meet the following criteria:
  • Participants must have FACE-Q Satisfaction with Skin Scale sum of raw scores of 39 or less
  • Participants must score "Very Dissatisfied" or "Somewhat Dissatisfied" on the following two questions:
  • How hydrated your facial skin looks?
  • How radiant your facial skin looks?

Exclusion criteria

  • Any skin condition in the face area that might not be suitable for injection
  • Uncontrolled systemic disease
  • History of anaphylactic shock, or allergy to lidocaine (or any amide-based anesthetics), hyaluronic acid (HA) products, or Streptococcal protein, or is planning to undergo desensitization therapy during the study
  • Active autoimmune disease
  • Tendency to develop hypertrophic scarring
  • Currently undergoing chemotherapy/radiotherapy
  • Is undergoing orthodontia before enrollment or is planning to undergo it during the study

Treatment and study plan

JUVÉDERM® VOLITE™

Device

Injection, intradermal

Other names: AGN-8015

Control

Other

No-treatment control

Primary outcomes

  1. Percentage of Participants Achieving "Responder" Status for Evaluating Investigator's (EI) Live Assessment of Global Aesthetic Improvement in Skin Quality on the Treatment Area Using the Global Aesthetic Improvement Scale (GAIS)

    Time frame: Month 2

    A "responder" is a participant who shows improvement in the overall aesthetic assessment on the treatment area using GAIS. GAIS is a 5-point scale ranging from 'Very Much Improved' to 'Worse'.

  2. Number of Participants with Adverse Events (AEs)

    Time frame: Up to approximately Month 12

    An AE is defined as any untoward medical occurrence, unintended disease or injury, or any untoward clinical signs (including an abnormal laboratory finding) in participants, users, or other persons, whether or not related to the investigational medical device, and whether anticipated or unanticipated.

Secondary outcomes

  1. Percentage of Participants Achieving "Responder" Status for Participant's Assessment of Global Aesthetic Improvement in Skin Quality on the Treatment Area using GAIS

    Time frame: Month 2

    A "responder" is a participant who shows improvement in the overall aesthetic assessment in the treatment area using GAIS. GAIS is a 5-point scale ranging from 'Very Much Improved' to 'Worse'.

  2. Percentage of Participants Achieving "Responder" Status for Treating Investigator's (TI) Assessment of Global Aesthetic Improvement of Skin Quality on the Treatment Area using GAIS

    Time frame: Month 2

    A "responder" is a participant who shows improvement in the overall aesthetic assessment in the treatment area using GAIS. GAIS is a 5-point scale ranging from 'Very Much Improved' to 'Worse'.

  3. Change from Baseline on the Overall Score of FACE-Q Satisfaction with Skin Scale

    Time frame: Month 2

    The FACE Q Satisfaction with Skin is a validated 12-item scale that asks subjects to report their level of satisfaction with how their facial skin looked "in the past week." Response options are on a 4-point Likert scale ranging from Very dissatisfied to Very Satisfied. Total score is Rasch transformed from 0 (worst) to 100 (best).

  4. Percentage of Participants with Responder Status based on EI's Live Assessments of Hydration Improvement on the Treatment Area Using the Aesthetic Improvement Scale for Hydration

    Time frame: Month 2

    A "responder" is a participant who shows aesthetic improvement in hydration of the treatment area ("Improved," "Much Improved," or "Very Much Improved" on the scale).

  5. Percentage of Participants with Responder Status based on EI's Live Assessments of Radiance Improvement on the Treatment Area Using the Aesthetic Improvement Scale for Radiance

    Time frame: Month 2

    A "responder" is a participant who shows aesthetic improvement in radiance of the treatment area ("Improved," "Much Improved," or "Very Much Improved" on the scale).

  6. Change from Baseline in Treatment Area Skin Elasticity Measurement

    Time frame: Month 2

    The trained designee will measure skin elasticity using the assigned instrument at the designated study visits.

  7. Change from Baseline in Treatment Area Skin Hydration Measurement

    Time frame: Month 2

    The trained designee will measure skin hydration using the assigned instrument at the designated study visits.

Sponsors and collaborators

Lead sponsor

AbbVie

Industry

Registry information

Official study title

Multicenter, Evaluator-Blinded, Randomized, No-Treatment Controlled Study of the Effectiveness and Safety of JUVÉDERM® VOLITE™ Injectable Gel for the Improvement in Skin Quality

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Aug 9, 2024
Registry last updated
Feb 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.